December 15th, 2015

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Glycomimetics Inc (NQ: GLYC )

3.790 USD UNCHANGED
Streaming Delayed Price Updated: 7:45 AM EST, Jan 28, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Glycomimetics Inc

< Previous 1 2 3 4 5 6 Next >
APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia
From ACN Newswire
APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia
From GlobeNewswire News Releases
New Supportive Efficacy Data for GlycoMimetics’ Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and Exposition
GlycoMimetics (Nasdaq: GLYC) today in an oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition disclosed new data reinforcing a now comprehensive set of... 
From Business Wire News Releases
GlycoMimetics’ Uproleselan in Combination With Venetoclax/HMA Shown to Break Chemoresistance, Reduce Tumor Burden and Increase Survival in AML Model
GlycoMimetics’ (Nasdaq: GLYC) product candidate uproleselan — when added to a combination therapy of venetoclax and a hypomethylating agent (HMA) — was shown today in an oral presentation to break... 
From Business Wire News Releases
GlycoMimetics to Present at Two Upcoming Virtual Healthcare Investor Conferences
GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that CEO Rachel King plans to present an overview of the company at the upcoming Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17... 
From Business Wire News Releases
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the third quarter ended September 30, 2020, and highlighted recent company events. Cash and cash equivalents at September 30,... 
From Business Wire News Releases
GlycoMimetics Program Data to be Highlighted Via Three Oral Presentations and Two Posters at 62nd American Society of Hematology Annual Meeting and Exposition
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that three abstracts including data from the Company’s clinical and research portfolio have been accepted for oral presentations and two abstracts... 
From Business Wire News Releases
GlycoMimetics to Report Third Quarter Financial Results on November 6, 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its third quarter financial results on Friday, November 6, 2020, at 8:30 a.m. ET. 
From Business Wire News Releases
New Pediatric and Secondary Endpoint Data from Rivipansel Phase 3 RESET Trial Presented at The Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) Meeting
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that new post hoc analyses of the Phase 3 RESET study evaluating the efficacy of rivipansel, its wholly-owned product candidate, in VOC show that... 
From Business Wire News Releases
FDA Grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for Treatment of Sickle Cell Disease
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a Rare Pediatric Disease designation for rivipansel for the treatment of... 
From Business Wire News Releases
GlycoMimetics to Present at Upcoming H.C. Wainwright & Co Annual Global Investment Virtual Conference
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will present at the upcoming H.C. Wainwright & Co 22nd Annual Global Investment Virtual Conference taking... 
From Business Wire News Releases
GlycoMimetics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that on August 14, 2020 the compensation committee of the Company’s Board of Directors approved the grant of non-qualified stock option... 
From Business Wire News Releases
New Preclinical GlycoMimetics Data Suggests Uproleselan With Venetoclax/HMA in AML May Prolong Survival
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced new preclinical data providing the first evidence that an E-selectin targeting strategy with uproleselan may help patients with acute myeloid leukemia... 
From Business Wire News Releases
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the second quarter ended June 30, 2020, and highlighted recent company events. Cash and cash equivalents at June 30, 2020... 
From Business Wire News Releases
GlycoMimetics to Report Second Quarter Financial Results on July 31, 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its second quarter financial results on Friday, July 31, 2020, at 8:30 a.m. ET. 
From Business Wire News Releases
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the compensation committee of the Company’s Board of Directors approved the grant on July 6, 2020 of a non-qualified stock option... 
From Business Wire News Releases
New Efficacy and Biomarker Data From Rivipansel Phase 3 RESET Trial to Be Presented at Sickle Cell Meeting
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that a post hoc analysis of the Phase 3 RESET study evaluating the efficacy of rivipansel , its wholly-owned development candidate, in acute... 
From Business Wire News Releases
GlycoMimetics to Present at Upcoming Jefferies Virtual Healthcare Conference
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the upcoming Jefferies Virtual Healthcare Conference. The presentation... 
From Business Wire News Releases
GlycoMimetics to Present New Preclinical Data Highlighting Biomarkers and Potential Expanded Pipeline Opportunities at Virtual AACR Annual Meeting 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that preclinical research on two of its drug candidates, uproleselan and GMI-1359, will be shared at the American Association for Cancer Research... 
From Business Wire News Releases
GlycoMimetics Announces Change to Virtual Meeting Format for 2020 Annual Meeting of Shareholders
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that its 2020 Annual Meeting of Shareholders (the “Annual Meeting”) will be held virtually instead of in person. Due to the ongoing public health... 
From Business Wire News Releases
GlycoMimetics Reports Operational Highlights and Financial Results for First Quarter 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the first quarter ended March 31, 2020 and highlighted recent company events. Cash and cash equivalents at March 31, 2020... 
From Business Wire News Releases
Compelling Data on Mechanism of Action for GlycoMimetics’ Late-stage Clinical Candidate Uproleselan Published in Nature Communications
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that important new preclinical data on the mechanism of action for its late-stage clinical candidate, uproleselan, are published in the April 27,... 
From Business Wire News Releases
GlycoMimetics to Report First Quarter Financial Results on May 1, 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its first quarter financial results on Friday, May 1, 2020, at 8:30 a.m. ET. 
From Business Wire News Releases
GlycoMimetics Appoints Dr. Myra Rosario Herrle as Vice President, Regulatory Affairs
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that veteran regulatory expert Myra Rosario Herrle, PhD, RPh, RAC, has joined the executive management team as Vice President, Regulatory Affairs. 
From Business Wire News Releases
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the compensation committee of the Company’s Board of Directors approved the grant on April 1, 2020 of non-qualified stock option... 
From Business Wire News Releases
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2019
GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the year and fourth quarter ended December 31, 2019 and highlighted recent company events including several accomplishments... 
From Business Wire News Releases
GlycoMimetics to Present at the Cowen and Company 40th Annual Health Care Conference 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the Cowen and Company 40th Annual Health Care Conference in Boston, on... 
From Business Wire News Releases
GlycoMimetics Advances GMI-1359 Program With Patent Issuance and FDA Designations
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced several achievements for its GMI-1359 development program, including the issuance of a new patent and key designations granted by the U.S. Food and... 
From Business Wire News Releases
First Patient With Advanced Breast Cancer Receives First Dose in Clinical Trial of GlycoMimetics' GMI-1359
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Duke University investigators have dosed the first patient in a proof-of-concept Phase 1b study to evaluate GlycoMimetics' novel GMI-1359 drug... 
From Business Wire News Releases
GlycoMimetics and Apollomics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Uproleselan and GMI-1687 in Greater China
GlycoMimetics, Inc. (NASDAQ: GLYC), a leader in the field of applied glycotechnology for cancer, and Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

3257 Dunmore Rd SE
Medicine Hat, AB T1B 3R2

[P] 403.527.1101
[F] 403.528.5696

Print Advertising: 403.528.5650
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2015 The Medicine Hat News, A Division of Continental Newspapers Canada Ltd.